Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza® (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Published
30 June 2014
From
Bristol-Myers Squibb press release
HCV drug out of the running

The German pharmaceutical giant Boehringer Ingelheim is stopping development of faldaprevir, its hepatitis C virus (HCV) drug.

Published
23 June 2014
From
MedPage Today
A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi

In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.

Published
23 June 2014
From
Reuters
UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

The US Food and Drug Administration (FDA) has granted priority review for AbbVie’s experimental all-oral regimen for treating adults infected with hepatitis C virus (HCV). The drug’s application under priority review means that FDA must evaluate the safety and effectiveness of the AbbVie regimen within six months before letting the manufacturer know whether they may take the product to market. AbbVie’s new regimen consists of an antiviral called ritonavir and a protease inhibitor called ABT-450, combined with an NS5A inhibitor called ombitasvir and the polymerase inhibitor dasabuvir. When taken together, these mechanisms are powerful enough to stop HCV. [Article source: http://www.techtimes.com]

Published
19 June 2014
From
CDC
AbbVie all-oral hepatitis C therapy gets rapid EU review

The U.S. drugmaker said on Tuesday the move by the European Medicines Agency meant that, if approved, its regimen could be available in the European Union in the first quarter of 2015. U.S. regulators have also granted the product priority review.

Published
17 June 2014
From
Reuters
NICE consults on draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

In draft recommendations published today healthcare guidance body NICE is asking Gilead Sciences for more information on its product sofosbuvir (Sovaldi), for the treatment of chronic hepatitis C. “The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients. However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer.”

Published
16 June 2014
From
NICE press release
Low uptake of HCV treatment in England will lead to substantial disease burden by 2035

Only 3% of patients with chronic hepatitis C virus (HCV) are treated for their infection each year in England, according to research published in the Journal of

Published
13 June 2014
By
Michael Carter
Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C

Perlmutter says that he believes Merck already had the best of two of the three drugs in the needed triple-drug combo: an NS5a inhibitor and a protease inhibitor. He expect that it may be possible to plan a combination trial of Merck’s drugs and Idenix’s lead nuke even before the deal closes.

Published
09 June 2014
From
Forbes
No critical interactions between ledipasvirsofosbuvir and certain key antiretrovirals

Ledipasvir/sofosbuvir, a fixed-dose coformulation of two direct-acting antivirals (DAAs) for HCV infection, did not have a clinically significant impact on five frequently used antiretrovirals--raltegravir, efavirenz, rilpivirine, and tenofovir/emtricitabine (TDF/FTC)--according to results of three studies in healthy volunteers.

Published
29 May 2014
From
NATAP
OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

Simeprevir provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment regimen, in combination with sofosbuvir, for appropriate patients in Europe

Published
16 May 2014
From
Reuters

Filter by country